Role of radiation therapy for retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative. Journal of surgical oncology Chouliaras, K., Senehi, R., Ethun, C. G., Poultsides, G., Grignol, V., Clarke, C. N., Roggin, K. K., Fields, R. C., Schwartz, P. B., Ronnekleiv-Kelly, S. M., D'Agostino, R. J., Johnson, E. N., Levine, E. A., Cardona, K., Votanopoulos, K. I. 2019


BACKGROUND: The use of radiation therapy in the treatment of retroperitoneal sarcomas has increased in recent years. Its impact on survival and recurrence is unclear.METHODS: A retrospective propensity score matched (PSM) analysis of patients with primary retroperitoneal soft tissue sarcomas, who underwent resection from 2000 to 2016 at eight institutions of the US Sarcoma Collaborative, was performed. Patients with metastatic disease, desmoid tumors, and palliative resections were excluded.RESULTS: Total 425 patients were included, 56 in the neoadjuvant radiation group (neo-RT), 75 in the adjuvant radiation group (adj-RT), and 294 in the no radiotherapy group (no-RT). Median age was 59.5 years, 186 (43.8%) were male with a median follow up of 31.4 months. R0 and R1 resection was achieved in 253 (61.1%) and 143 (34.5%), respectively. Overall 1:1 match of 46 adj-RT and 59 neo-RT patients was performed using histology, sex, age, race, functional status, tumor size, grade, resection status, and chemotherapy. Unadjusted recurrence-free survival (RFS) was 35.9 months (no-RT) vs 33.5 months (neo-RT) and 27.2 months (adj-RT), P=.43 and P=.84, respectively. In the PSM, RFS was 17.6 months (no-RT) vs 33.9 months (neo-RT), P=.28 and 19 months (no-RT) vs 27.2 months (adj-RT), P=.1.CONCLUSIONS: Use of radiotherapy, both in adjuvent or neoadjuvent setting, was not associated with improved survival or reduced recurrence rate.

View details for DOI 10.1002/jso.25694

View details for PubMedID 31486096